Oppenheimer Initiates Passage Bio Coverage with Outperform Rating and $30 Target

Oppenheimer has initiated coverage of Passage Bio (PASG) with an Outperform rating and a price target of $30.00. This target implies a significant potential upside of approximately 385% from the stock's current market price. The firm's bullish outlook is primarily driven by the potential of the company's lead asset, PBFT02, a treatment for dementia. Analysts project that PBFT02 could reach $1 billion in risk-adjusted peak sales by the year 2040. Oppenheimer views the stock's 46% year-to-date decline as an overreaction to external market volatility and competitor setbacks. Consequently, the investment firm identifies the current valuation as a compelling buying opportunity for investors. The initiation highlights the firm's confidence in the long-term clinical prospects of Passage Bio's pipeline.